These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37198888)

  • 21. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab).
    Schmick K; Grabbe J
    Br J Dermatol; 2004 Feb; 150(2):367. PubMed ID: 14996114
    [No Abstract]   [Full Text] [Related]  

  • 22. Risankizumab in moderate-to-severe plaque psoriasis.
    Serrano L; Maloney V; Gordon KB
    Immunotherapy; 2019 Nov; 11(16):1357-1370. PubMed ID: 31578912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acrodermatitis continua of Hallopeau in an elderly patient successfully and rapidly treated with risankizumab: a case report.
    Orsini D; Iacovelli P; Frascione P; Pacifico A
    J Dermatolog Treat; 2023 Dec; 34(1):2229468. PubMed ID: 37381703
    [No Abstract]   [Full Text] [Related]  

  • 24. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
    Suleiman AA; Khatri A; Minocha M; Othman AA
    Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
    Okubo Y; Mabuchi T; Iwatsuki K; Elmaraghy H; Torisu-Itakura H; Morisaki Y; Nakajo K
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):325-332. PubMed ID: 30317671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients.
    Pang Y; Khatri A; Suleiman AA; Othman AA
    Clin Pharmacokinet; 2020 Mar; 59(3):311-326. PubMed ID: 31758502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risankizumab for the treatment of moderate to severe psoriasis.
    Chiricozzi A; Antonioli L; Panduri S; Fornai M; Romanelli M; Blandizzi C
    Expert Opin Biol Ther; 2019 Jan; 19(1):1-8. PubMed ID: 30462554
    [No Abstract]   [Full Text] [Related]  

  • 28. Complete Clearance of Pustular Psoriasis After A Single Dose of Risankizumab.
    Hermann AE; Weis SE
    HCA Healthc J Med; 2023; 4(2):209-213. PubMed ID: 37424986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority.
    Witjes H; Khatri A; Diderichsen PM; Mandema J; Othman AA
    Clin Pharmacol Ther; 2020 Feb; 107(2):435-442. PubMed ID: 31502263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature.
    McDonald J; Maliyar K; Gooderham MJ
    Skin Therapy Lett; 2020 May; 25(3):1-4. PubMed ID: 32510689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risankizumab for the treatment of psoriasis.
    Gu C; Yang J
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of pustular psoriasis with infliximab.
    Weishaupt C; Metze D; Luger TA; Ständer S
    J Dtsch Dermatol Ges; 2007 May; 5(5):397-9. PubMed ID: 17451384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generalized pustular psoriasis (von Zumbusch).
    Romiti R; Hirayama ALDS; Arnone M; Magalhães RF
    An Bras Dermatol; 2022; 97(1):63-74. PubMed ID: 34838431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world data on the clinical use of secukinumab in pediatric generalized pustular psoriasis: A 48-week retrospective study.
    Ruan SF; Zhang LL; Liu Z; Lin TT; Wang HQ; Xu QY; Xiang N; Cheng B; Liu T; Ha HY; Gong T; Ji C
    J Am Acad Dermatol; 2023 Jan; 88(1):243-246. PubMed ID: 35588923
    [No Abstract]   [Full Text] [Related]  

  • 35. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
    Visvanathan S; Baum P; Vinisko R; Schmid R; Flack M; Lalovic B; Kleiner O; Fuentes-Duculan J; Garcet S; Davis JW; Grebe KM; Fine JS; Padula SJ; Krueger JG
    J Allergy Clin Immunol; 2019 Jun; 143(6):2158-2169. PubMed ID: 30578873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secukinumab in the Treatment of Generalized Pustular Psoriasis: A Case report.
    Polesie S; Lidholm AG
    Acta Derm Venereol; 2017 Jan; 97(1):124-125. PubMed ID: 27231055
    [No Abstract]   [Full Text] [Related]  

  • 37. Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis.
    Mugheddu C; Atzori L; Lappi A; Pau M; Murgia S; Rongioletti F
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):e420-e421. PubMed ID: 28319281
    [No Abstract]   [Full Text] [Related]  

  • 38. Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers.
    Orsini D; Gargiulo L; Ibba L; Cascio Ingurgio R; Valenti M; Perugini C; Pacifico A; Maramao FS; Frascione P; Costanzo A; Narcisi A
    J Dermatolog Treat; 2023 Dec; 34(1):2220849. PubMed ID: 37288760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Occurrence of plantar pustular psoriasis during treatment with infliximab.
    English PL; Vender R
    J Cutan Med Surg; 2009; 13(1):40-2. PubMed ID: 19298770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment.
    Skrabl-Baumgartner A; Weger W; Salmhofer W; Jahnel J
    Pediatr Dermatol; 2015; 32(1):e13-4. PubMed ID: 25644044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.